Cybin, a leading biotechnology company, has announced its acquisition of Small Pharma, an innovative U.K.-based company specializing in short-duration psychedelic therapies for mental health conditions. The transaction, an all-share deal, marks an exciting development in the field of mental health treatments.
Exchange Ratio and Consideration
As part of the agreement, Small Pharma shareholders will receive 0.2409 common shares of Cybin for each share of Small Pharma owned. Based on the closing price of Cybin on Friday, this translates to a consideration of 10 Canadian cents (7 U.S. cents) per Small Pharma Share, representing a significant premium of 43.64% based on the 30-day volume weighted average prices.
Following the transaction, the combined company will have Cybin shareholders holding 74.5% of the ownership, with Small Pharma securityholders owning 25.5%.
Leadership and Integration
Under the leadership of Doug Drysdale, Cybin's chief executive, the newly merged company will incorporate the expertise and talent of both organizations. Small Pharma's senior management and staff will seamlessly integrate with the existing Cybin team, ensuring a unified approach to driving progress in the field of mental health therapies.